Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer

Inclusion Criteria: * Patients with histologically confirmed stage IV renal cancer who have stable (including those rendered to be in remission) or progressive disease * Human lymphocyte antigen (HLA) genotypically identical related donor willing to undergo leukapheresis initially for collection of peripheral blood stem cells (PBSC) and subsequently for collection of peripheral blood mononuclear cells (PBMC) * Ionized calcium level within normal limits * DONOR: HLA genotypically identical family member (excluding identical twins) * DONOR: Donor must consent to filgrastim (G-CSF) administration and leukapheresis * DONOR: Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter (femoral, subclavian) * DONOR: Age \< 75 years Exclusion Criteria: * Patients who have positive serologies for human immunodeficiency virus (HIV)1 and 2, human T-lymphotropic virus (HTLV)-1 * Patients unwilling to use contraceptive techniques during and for 12 months following treatment * Serum creatinine \> 2.0; the Fred Hutchinson Cancer Research Center (FHCRC) Patient Care Conference (PCC) may approve patients with elevated serum creatinine following presentation and approval; centers outside the FHCRC that have a PCC or equivalent should obtain their institutional approval; if there is not a comparable group at the institution, please contact the FHCRC Principal Investigator for FHCRC approval through PCC * Cardiac ejection fraction \< 50%; ejection fraction is required if the patient has a history of anthracyclines or history of cardiac disease * Diffusion capacity of carbon monoxide (DLCO) \< 50% of predicted, total lung capacity (TLC) \< 50%, forced expiratory volume in one second (FEV1) \< 50% * Liver function tests including total bilirubin, serum glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetic transaminase (SGOT) \> 2 x the upper limit of normal unless due to the malignancy * Karnofsky score \< 80 * Brain metastasis * Ongoing active bacterial, viral or fungal infection * Pregnancy or breastfeeding * Patients with other active non-hematologic malignancies (except non-melanoma skin cancers) * Patients with a history of other non-hematologic malignancies (except non-melanoma skin cancers) currently in a complete remission, who are less than 5 years from the time of complete remission, and have a \> 20% risk of disease recurrence * The addition of cytotoxic agents for "cytoreduction" with the exception of Gleevec (imatinib mesylate), cytokine therapy, hydroxyurea, low dose cytarabine, chlorambucil, or rituxan will not be allowed within three weeks of the initiation of conditioning * DONOR: Age less than 12 years * DONOR: Pregnancy * DONOR: Infection with HIV * DONOR: Inability to achieve adequate venous access * DONOR: Known allergy to G-CSF * DONOR: Current serious systemic illness * DONOR: Failure to meet criteria for donation as described in the Standard Practice Guidelines of the institution